Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.
Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.
However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.
This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors.
However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.
This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
Location: France, Ile-de-France, Paris
Employees: 11-50
Total raised: $30.46M
Founded date: 2013
Investors 4
| Date | Name | Website |
| - | Newton Bio... | newtonbioc... |
| - | Karista Ve... | karista.vc |
| - | Agoranov | agoranov.c... |
| - | GO Capital... | gocapital.... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 07.11.2019 | Series B | $7.75M | - |
| 18.10.2018 | Series B | $17.52M | - |
| 08.01.2018 | - | $2.03M | - |
| 07.02.2017 | - | $1.6M | - |
| 11.07.2016 | - | $1.55M | - |
Mentions in press and media 13
| Date | Title | Description |
| 03.06.2024 | Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies | Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies New analyses of ACTISAVE phase 2/3 study show positive trends for glenzocimab in subpopulations of patients Continuation of cl... |
| 02.09.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 2nd Sept 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 01.09.2023 | ACTIMIS Post-hoc Results on Imaging Stroke Data Using Artificial Intelligence Reinforces Glenzocimab Mode of Action in Stroke Patients | Acticor Biotech, a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced the results of its collaboration with Brainomix Limited, to further explore th... |
| 12.04.2023 | Startup Showcase: Acticor Biotech – Innovating Stroke Treatment | Looking for innovative solutions to treat ischemic stroke? Look no further than Acticor Biotech, a biopharmaceutical company developing a breakthrough drug for the treatment of ischemic stroke. With millions of people worldwide suffering fr... |
| 12.01.2022 | Acticor Biotech SAS : Inside Information / Other news releases | PRESS RELEASE Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux Paris, France, January 12, 2022 at 06:00 pm CET - ACTICOR BIOTECH (ISIN : FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company... |
| 04.11.2021 | Acticor Biotech lists on Euronext Growth Paris | 5th listing of a biotech company on Euronext Paris in 2021. Euronext today congratulates Acticor Biotech, a biopharmaceutical company specialised in the treatment of thrombotic diseases, on its listing on Euronext Growth Paris (ticker code:... |
| 06.11.2019 | Acticor Biotech Raises Additional €7M; Closes Series B At €22.3M | Acticor Biotech, a Paris, France-based clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, raised €7m in addition to its Series B funding, which is now completed at €22.3... |
| 18.10.2018 | Acticor Biotech Raises €15.3M In Series B Financing | Acticor Biotech, a Paris, France-based clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, completed a €15.3m Series B round of financing. The round was led by Ne... |
| 18.10.2018 | Term Sheet — Thursday, October 18 | 5 Qs WITH A DEALMAKER Founders Fund partner Cyan Banister says capitalism saved her life. Paid Content You can't secure what you can't see From ExtraHop “Literally it was a paycheck,” she told Term Sheet. “I realized that if I work hard, I ... |
| 08.01.2018 | Acticor Biotech Closes €1.7M Equity Financing | Acticor Biotech, a Paris, France-based clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, closed a €1.7m equity financing. The ro... |
Show more